{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:14:53Z","timestamp":1793121293607,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clgc.2023.02.009","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:37:51Z","timestamp":1679024271000},"page":"403-414.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Urinary Neuroendocrine Neoplasms Treated in the \u201cModern Era\u201d: A Multicenter Retrospective Review"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-3766","authenticated-orcid":false,"given":"Bryan Khuong","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McGarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-882X","authenticated-orcid":false,"given":"Alan","family":"Paciorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-2548","authenticated-orcid":false,"given":"Kathleen","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3617-2627","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1385-9995","authenticated-orcid":false,"given":"Nitya","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7754-6552","authenticated-orcid":false,"given":"Emily","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-1257","authenticated-orcid":false,"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.02.009_bib0001","doi-asserted-by":"crossref","unstructured":"Yao JC, Hassan M, Phan A, et\u00a0al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. 2008;26(18):3063-3072. doi:doi:10.1200\/JCO.2007.15.4377.","DOI":"10.1200\/JCO.2007.15.4377"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.009_bib0002","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.21873\/anticanres.12589","article-title":"The colorful palette of neuroendocrine neoplasms in the genitourinary tract","volume":"38","author":"P\u00f3sfai","year":"2018","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.009_bib0003","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2023.02.009_bib0004","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2023.02.009_bib0005","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1503\/cmaj.160771","article-title":"Principles of diagnosis and management of neuroendocrine tumours","volume":"189","author":"Raphael","year":"2017","journal-title":"Cmaj"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.009_bib0006","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.009_bib0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","article-title":"Survival According to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas","volume":"27","author":"Dasari","year":"2022","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2023.02.009_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clgc.2020.10.010","article-title":"Clinicopathologic features and survival outcomes for primary renal neuroendocrine neoplasms","volume":"19","author":"Yi","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.009_bib0009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (High-Grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.009_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2019.11.003","article-title":"Renal neuroendocrine neoplasms: a single-center experience","volume":"18","author":"McGarrah","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.009_bib0011","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12253-018-0481-x","article-title":"Five new cases of primary renal carcinoid tumor: case reports and literature review","volume":"26","author":"Rosenberg","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clgc.2023.02.009_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","article-title":"Neuroendocrine tumors of genitourinary tract: recent advances","volume":"42","author":"Shehabeldin","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"23","key":"10.1016\/j.clgc.2023.02.009_bib0013","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1002\/cncr.26197","article-title":"A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends","volume":"117","author":"Koay","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0014","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12022-016-9444-5","article-title":"Neuroendocrine Tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics","volume":"27","author":"Kouba","year":"2016","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.009_bib0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.02.009_bib0016","first-page":"224","article-title":"Bladder cancer","volume":"6","author":"Price","year":"1966","journal-title":"Proc Can Cancer Conf"},{"key":"10.1016\/j.clgc.2023.02.009_sbref0017","series-title":"Network Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors, Version 1","year":"2022"},{"issue":"23","key":"10.1016\/j.clgc.2023.02.009_bib0018","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.clgc.2023.02.009_bib0019","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clgc.2023.02.009_bib0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual Anti\u2013CTLA\u20134 and Anti\u2013PD\u20131 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2023.02.009_bib0021","doi-asserted-by":"crossref","unstructured":"Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2022;7(1):100364. doi:10.1016\/j.esmoop.2021.100364.","DOI":"10.1016\/j.esmoop.2021.100364"},{"issue":"22","key":"10.1016\/j.clgc.2023.02.009_bib0022","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2023.02.009_bib0023","first-page":"1100","article-title":"Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study","volume":"112","author":"Turbat-Herrera","year":"1988","journal-title":"Arch Pathol & Lab Med"},{"issue":"8","key":"10.1016\/j.clgc.2023.02.009_bib0024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1442-2042.2001.00347.x","article-title":"Progression of prostate cancer to neuroendocrine cell tumor","volume":"8","author":"Tanaka","year":"2001","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.009_bib0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2023.02.009_bib0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","article-title":"Overview of Sankey flow diagrams: Focusing on symptom trajectories in older adults with advanced cancer","volume":"13","author":"Otto","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2023.02.009_bib0027","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.clgc.2023.02.009_bib0028","first-page":"4529","article-title":"Analysis of clinicopathological features and prognostic factors in 39 cases of bladder neuroendocrine carcinoma","volume":"37","author":"Zhou","year":"2017","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.clgc.2023.02.009_bib0029","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/PAS.0000000000001740","article-title":"Urinary large cell neuroendocrine carcinoma: a clinicopathologic analysis of 22 cases","volume":"45","author":"Wang","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2023.02.009_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.humpath.2021.04.006","article-title":"Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity","volume":"114","author":"Amin","year":"2021","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.clgc.2023.02.009_sbref0031","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin","volume":"68","author":"Mortel","year":"1991","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2023.02.009_bib0032","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2023.02.009_bib0033","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2017.04.009","article-title":"Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort","volume":"79","author":"Walter","year":"2017","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.clgc.2023.02.009_bib0034","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.clgc.2023.02.009_bib0035","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","article-title":"Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer","volume":"27","author":"Siefker-Radtke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.009_bib0036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.009_bib0037","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MPA.0000000000001529","article-title":"Efficacy of second-line chemotherapy in extrapulmonary neuroendocrine carcinoma","volume":"49","author":"McGarrah","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.clgc.2023.02.009_bib0038","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer, Version 1. 2023. 2023. Published online. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 9\/27\/2022."},{"issue":"11","key":"10.1016\/j.clgc.2023.02.009_bib0039","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/onco.13923","article-title":"Temozolomide in Grade 3 gastroenteropancreatic neuroendocrine neoplasms: a multicenter retrospective review","volume":"26","author":"Chan","year":"2021","journal-title":"Oncologist"},{"issue":"20","key":"10.1016\/j.clgc.2023.02.009_bib0040","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2023.02.009_bib0041","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0042","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-20-0382","article-title":"Spartalizumab in metastatic, well\/poorly differentiated neuroendocrine neoplasms","volume":"28","author":"Yao","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0043","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clgc.2023.02.009_bib0044","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","article-title":"Avelumab in unresectable\/metastatic, progressive, grade 2\u20133 neuroendocrine neoplasms (NENs): Combined results from NET- 001 and NET-002 trials","volume":"169","author":"Chan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.02.009_bib0045","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2021.39.15_suppl.4148","article-title":"Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab\u00a0+\u00a0chemotherapy)","volume":"39","author":"Chan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2023.02.009_bib0046","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket Trial of Dual Anti\u2013CTLA-4 and Anti\u2013PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.clgc.2023.02.009_bib0047","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: A subgroup analysis of the CA209-538 clinical trial for rare cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.009_bib0048","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MPA.0000000000001794","article-title":"Efficacy of checkpoint inhibitors in neuroendocrine neoplasms: mayo clinic experience","volume":"50","author":"Gile","year":"2021","journal-title":"Pancreas"},{"issue":"10","key":"10.1016\/j.clgc.2023.02.009_bib0049","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/PAS.0b013e318042d596","article-title":"Renal carcinoid tumor: a clinicopathologic study of 21 cases","volume":"31","author":"Hansel","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"6 Pt 1","key":"10.1016\/j.clgc.2023.02.009_bib0050","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.juro.2006.07.129","article-title":"Primary carcinoid tumors of the kidney","volume":"176","author":"Romero","year":"2006","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.009_bib0051","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival","volume":"104","author":"Rinke","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0052","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2023.02.009_bib0053","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2023.02.009_bib0054","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.009_bib0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2023.02.009_bib0056","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2017.35.4_suppl.228","article-title":"Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.02.009_bib0057","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2019.37.15_suppl.4005","article-title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)","volume":"37","author":"Bergsland","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2023.02.009_bib0058","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3_suppl","key":"10.1016\/j.clgc.2023.02.009_bib0059","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.2021.39.3_suppl.360","article-title":"A phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)","volume":"39","author":"Garcia-Carbonero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2023.02.009_bib0060","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1 & 2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT Trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2023.02.009_bib0061","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2023.02.009_bib0062","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","article-title":"A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)","volume":"36","author":"Kunz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2023.02.009_bib0063","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.5858\/2006-130-1693-CTOTUT","article-title":"Carcinoid tumors of the urinary tract and prostate","volume":"130","author":"Murali","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.02.009_bib0064","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s00261-016-1012-4","article-title":"Neuroendocrine neoplasms of the genitourinary tract in adults: cross-sectional imaging spectrum","volume":"42","author":"Katabathina","year":"2017","journal-title":"Abdom Radiol"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2013.02.003","article-title":"Primary renal carcinoid: treatment and prognosis","volume":"87","author":"Korkmaz","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.009_bib0066","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MPA.0000000000002014","article-title":"Pancreatic neuroendocrine tumors: the effect of facility type on patient survival","volume":"51","author":"Lee","year":"2022","journal-title":"Pancreas"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:23Z","timestamp":1761565103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1558767323000423"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.02.009","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary Neuroendocrine Neoplasms Treated in the \u201cModern Era\u201d: A Multicenter Retrospective Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}